Table 4.
Main diagnostic finding established in all enteroscopies according to the route of insertion and type of enteroscope used
| Diagnosis | DBE | SBE | SE | Total |
|---|---|---|---|---|
| Oral route of insertion | ||||
| Normal | 284 (5 a) | 78 (1 a) | 1 | 363 |
| Vascular lesion(s) | 216 | 63 | 4 | 283 |
| • Angiectasia(s) | 206 | 57 (2 a) | 4 | 267 |
| • Dieulafoy | 2 | 3 | – | 5 |
| • Active bleeding | 6 (1 a) | – | – | 6 |
| • Portal hypertensive enteropathy | 2 | 3 (1 a) | – | 5 |
| Inflammatory lesion(s) | 95 | 25 | 1 | 121 |
| • Crohn’s disease | 35 | 13 (1 a) | 1 | 49 |
| • Non-specific enteritis | 34 (2 a) | 12 | – | 46 |
| • Celiac disease | 14 | - | – | 14 |
| • NSAIDs enteropathy | 9 | - | – | 9 |
| • Radiation enteritis | 3 | - | – | 3 |
| Polyps/polyposis | 92 | 26 | – | 118 |
| • PJS | 64 | 2 | – | 66 |
| • FAP/MAP | 9 | 1 | – | 10 |
| • Polyp(s) | 19 (1 a) | 23 (1 a) | – | 42 |
| Tumor | 62 | 9 (1 a) | – | 71 |
| Stenosis | 12 | 11 (1 a) | – | 23 |
| Extra-small-bowel findings | 10 | – | – | 10 |
| Other findings | 28 | 27 (1 a) | – | 55 |
| Total | 799 | 239 | 6 | 1044 |
| Anal route of insertion | DBE | SBE | SE | Total |
| Normal | 122 | 39 | – | 161 |
| Inflammatory lesion(s) | 63 | 43 | – | 106 |
| • Crohn’s disease | 34 | 35 | – | 69 |
| • Non-specific enteritis | 25 | 6 | – | 31 |
| • Radiation enteritis | 2 | 2 | – | 4 |
| • NSAIDs enteropathy | 1 | – | – | 1 |
| • Celiac disease | 1 | – | – | 1 |
| Vascular lesion(s) | 17 | 4 | – | 21 |
| • Angiectasia(s) | 16 | 4 | – | 20 |
| • Active bleeding | 1 | - | - | 1 |
| Stenosis | 9 | 6 | – | 15 |
| Extra-small bowel findings | 11 | 2 | – | 13 |
| Polyps/polyposis | 10 | 3 | – | 13 |
| • PJS | 2 | 1 | – | 3 |
| • FAP/MAP | 1 | – | – | 1 |
| • Polyp(s) | 7 | 2 | – | 9 |
| Tumor | 9 | 2 | – | 11 |
| Other findings | 14 | 13 | – | 27 |
| Total | 255 | 112 | – | 367 |
| All patients | ||||
| Normal | 406 | 117 | 1 | 524 |
| Vascular lesion(s) | 233 | 67 | 4 | 304 |
| • Angiectasia(s) | 222 | 61 | 4 | 287 |
| • Active bleeding | 7 | – | – | 7 |
| • Dieulafoy | 2 | 3 | – | 5 |
| • Portal hypertensive enteropathy | 2 | 3 | – | 5 |
| Inflammatory lesion(s) | 158 | 68 | 1 | 227 |
| • Crohn’s disease | 69 | 48 | 1 | 118 |
| • Non-specific enteritis | 59 | 18 | – | 77 |
| • Celiac disease | 15 | – | – | 15 |
| • NSAIDs enteropathy | 10 | – | – | 10 |
| • Radiation enteritis | 5 | 2 | – | 7 |
| Polyp(s)/polyposis | 102 | 29 | – | 131 |
| • PJS | 66 | 3 | – | 69 |
| • FAP/MAP | 10 | 1 | – | 11 |
| • Polyp(s) | 26 | 25 | – | 51 |
| Tumor | 71 | 11 | – | 82 |
| Stenosis | 21 | 17 | – | 38 |
| Extra-small bowel findings | 21 | 2 | – | 23 |
| Other findings | 42 | 40 | – | 82 |
| Total | 1054 | 351 | 6 | 1411 |
a
Number of patients in which oral and anal DAE was performed the same day. These procedures are recorded as a single procedure, and detailed in the oral route of insertion section. DAE: device-assisted enteroscopy; SBE: single-balloon enteroscopy; SE: spiral enteroscopy; NSAIDs: nonsteroidal anti-inflammatory drugs; PJS: Peutz-Jeghers syndrome; FAP: familial adenomatous polyposis; MAP. MUTYH-associated polyposis.